Nuclear receptor subfamily 2 group F member 6 (NR2F6) (NR2F6)

Nuclear receptor subfamily 2 group F member 6 (NR2F6), also known as EAR-2, is an orphan nuclear receptor that functions as a critical intracellular immune checkpoint and transcriptional regulator. It is predominantly expressed in immune cells, where it acts as a repressor of T-cell activation by inhibiting the expression of essential cytokines like IL-2 and IFN-gamma through the antagonism of NFAT and AP-1 transcription factors. In the context of oncology, NR2F6 is frequently upregulated in tumor-infiltrating lymphocytes and various solid tumors, contributing to immune evasion and T-cell exhaustion. Engineering CAR-T cells to lack NR2F6 is a potent strategy to enhance their anti-tumor efficacy, particularly against solid tumors that exploit checkpoint pathways to suppress immune responses. By removing this internal regulatory brake, engineered cells exhibit superior persistence and effector functions. While small-molecule inhibitors of NR2F6 are also under investigation to boost systemic immunity, genetic modification of adoptive cell therapies offers a targeted approach to overcome the immunosuppressive microenvironment. However, therapeutic manipulation of NR2F6 must be carefully managed due to its role in maintaining immunological tolerance, as its deficiency is associated with increased susceptibility to autoimmunity and neuroinflammation.

Other names

EAR-2EAR2COUP-TFIIIV-erbA-related protein 2ERBAL2Nuclear receptor V-erbA-relatedERBA-related gene-2

NR2F6 acts as an intracellular immune checkpoint by transcriptionally repressing key effector cytokines such as IL-2, IFN-gamma, and TNF-alpha in T cells. It achieves this by binding to specific DNA motifs (GGTCA) and antagonizing the DNA-binding activity of transcription factors NFAT and AP-1. In engineered CAR-T cells, the genetic ablation (knockout) of NR2F6 via CRISPR-Cas9 or other editing tools removes this 'molecular brake,' thereby enhancing T-cell effector function, increasing cytokine production, and preventing exhaustion in the immunosuppressive tumor microenvironment.